Results from a U.S. trial of AstraZeneca’s COVID-19 vaccine may have included “outdated information” and that could mean the company provided an incomplete view of efficacy data, American federal health officials said early Tuesday.

AstraZeneca said in a statement that the data it released Monday included cases up to Feb. 17, as the study rules specified, and that it was continuing to analyze cases that have occurred since then. The company said that a preliminary analysis of data that has continued to roll in was consistent with what it had already reported. It promised an update within 48 hours.

AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that some experts hoped would help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.

In the study of more than 30,000 people, the company reported that the vaccine was found to be 79% effective at preventing symptomatic cases of COVID-19 — including in older adults. There were no severe illnesses or hospitalizations among vaccinated volunteers, compared with five such cases in participants who received dummy shots — a small number, but consistent with findings from Britain and other countries that the vaccine protects against the worst of the disease.

AstraZeneca also said the study’s independent safety monitors found no serious side effects, including no increased risk of rare blood clots like those identified in Europe, a scare that led numerous countries to briefly suspend vaccinations last week.

But just hours after those encouraging results were reported, the U.S. National Institute of Allergy and Infectious Diseases issued an unusual statement.

The agency said the Data and Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.”

“We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible,” the statement added.

In previous vaccine trials, as is the situation here, cases have continued to accrue, even as companies began to release their data. But the AstraZeneca circumstance is unusual in drawing the concern of the data monitoring board.

The Food and Drug Administration reviews the most up-to-date trial findings when it assesses the vaccines.

The company has said it aims to file an application with the FDA in the coming weeks, and the government’s outside advisers will then publicly debate the evidence.

Authorization and guidelines for use of the vaccine in the United States will be determined by the FDA and Centers for Disease Control and Prevention after thorough review of the data by independent advisory committees.

 

 

Related Stories
‹
Astrazeneca: U.S. Data Shows Vaccine Effective for All Ages
Written by MARIA CHENG and LAURAN NEERGAARD AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United States, the company announced Monday. AstraZeneca said its experts did not identify any safety concerns related to the vaccine, including finding no […]
EU Regulator Reviews Astrazeneca Shot and Blood Clot Links
Written by MARIA CHENG and FRANK JORDANS The world awaited the results Thursday of an initial European investigation into whether there is any evidence that the AstraZeneca coronavirus vaccine is linked to blood clots reported in small numbers of recipients of the shot. Concerns over the clotting led more than a dozen European countries to suspend […]
Moderna Seeks FDA Authorization for 4th Dose of COVID Shot
Written by ZEKE MILLER Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults. The request is broader than rival pharmaceutical company Pfizer’s request earlier this week for the regulator to approve a booster shot for all seniors. In […]
Pfizer Says COVID Booster Offers Protection Against Omicron
Written by LAURAN NEERGAARD Pfizer said Wednesday that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant even though the initial two doses appear significantly less effective. Pfizer and its partner BioNTech said that while two doses may not be protective enough to prevent infection, lab tests showed a booster […]
US Expands COVID Boosters to All Adults, Final Hurdle Ahead
Written by LAURAN NEERGAARD and MATTHEW PERRONE U.S. regulators on Friday moved to open up COVID-19 booster shots to all adults, expanding the government’s campaign to shore up protection and get ahead of rising coronavirus cases that may worsen with the holidays. Pfizer and Moderna announced the Food and Drug Administration’s decision after at least […]
US Gives Final Clearance to COVID-19 Shots for Kids 5 to 11
U.S. health officials on Tuesday gave the final signoff to Pfizer’s kid-size COVID-19 shot, a milestone that opens a major expansion of the nation’s vaccination campaign to children as young as 5. The Food and Drug Administration already authorized the shots for children ages 5 to 11 — doses just a third of the amount […]
Pfizer Asks US To Allow COVID Shots for Kids Ages 5 to 11
Written by LAURAN NEERGAARD Pfizer asked the U.S. government Thursday to allow use of its COVID-19 vaccine in children ages 5 to 11 — and if regulators agree, shots could begin within a matter of weeks. Many parents and pediatricians are clamoring for protection for children younger than 12, today’s age cutoff for the vaccine […]
U.S. Parents Excited Over Prospect of Virus Shots for Children
Written by HEATHER HOLLINGSWORTH and TODD RICHMOND After more than a year of fretting over her 13-year son with a rare liver disease, Heather Ousley broke into tears when she learned that he and millions of other youngsters could soon be eligible for the COVID-19 vaccine. “This day is the best day in the history of […]
EU Moves Toward Stricter Export Controls for COVID Vaccines
Written by RAF CASERT The European Union is moving toward stricter export controls to ensure that there are more COVID-19 shot supplies for the bloc which should boost its flagging vaccine drive at a time of another surge of the coronavirus pandemic on the continent. The EU’s executive body said Wednesday on the eve of a […]
A Rapid COVID-19 Vaccine Rollout Backfired in Some U.S. States
Written by CARLA K. JOHNSON and NICKY FORSTER Despite the clamor to speed up the U.S. vaccination drive against COVID-19 and get the country back to normal, the first three months of the rollout suggest faster is not necessarily better. A surprising new analysis found that states such as South Carolina and Florida that raced ahead […]
›